NewsBenzinga罗氏获FDA批准 Tecentriq 联合治疗用于III期DMMR结肠癌辅助治疗;ATOMIC试验显示36个月无病生存率达86%,高于单纯化疗的76% 罗氏获FDA批准 Tecentriq 联合治疗用于III期DMMR结肠癌辅助治疗;ATOMIC试验显示36个月无病生存率达86%,高于单纯化疗的76% Benzinga 2026.10.09 06:05 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning Royal Caribbean Group Stock In The Last 15 Years Bitcoin Faces Historic Capitulation Levels: Can $62,000 Support Hold? $1000 Invested In Teck Resources 5 Years Ago Would Be Worth This Much Today 'Microsoft Executive Says Nvidia Drama Could Boost Rival Chips'- Bloomberg If You Invested $1000 In iShares Core S&P U.S. Growth ETF Stock 10 Years Ago, You Would Have This Much Today Kimball Electronics Says Co. Intends To Change Name To Kimball Solutions, Effective July 1, 2027; Expects To Change Ticker Symbol To KMBL
If You Invested $1000 In iShares Core S&P U.S. Growth ETF Stock 10 Years Ago, You Would Have This Much Today
Kimball Electronics Says Co. Intends To Change Name To Kimball Solutions, Effective July 1, 2027; Expects To Change Ticker Symbol To KMBL